Clinical Trial

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.

A new non-thermal ablation technology shows long-term success in shrinking thyroid nodules with high patient satisfaction, potentially disrupting surgical norms.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

Early access programs for a rare blindness therapy in France, Israel, and the US offer hope to patients and provide a crucial financial lifeline for the company.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

Investors watch closely as CytoSorbents balances a push for profitability with high-stakes regulatory hurdles for its life-saving blood purification tech.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.